Tenax Therapeutics, Inc.
TENX· Nasdaq
TENXTenax Therapeutics, Inc.
Filed May 14, 2024 · 10-Q · 44 days after period end · 0001654954-24-006228
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Net Income | -$3.80M | -$1.41M | -$2.72M | -$23.75M |
| EPS Diluted | -$3.12 | — | — | -$1.64 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 14, 2024 · 44 d after period end
